Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Earnings for Revolution Medicines, Inc. (RVMD)
Earnings in 2023 (TTM): $-439,891,000
According to Revolution Medicines, Inc.'s latest financial reports the company's current earnings (TTM) are $-439,891,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Revolution Medicines, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-439,891,000 | $-436,367,000 |
| 2022 | $-249,125,000 | $-248,705,000 |
| 2021 | $-187,091,000 | $-179,771,000 |
| 2020 | $-108,530,000 | $-108,159,000 |
| 2019 | $-52,037,000 | $-47,664,000 |
| 2018 | $-41,789,000 | $-41,789,000 |
| 2017 | $-31,127,000 | $-31,127,000 |